Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.

[1]  Rui Zhong,et al.  The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  P. Trivedi,et al.  Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  A. Granito,et al.  Surrogate Markers for Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. , 2020, The American journal of gastroenterology.

[4]  gui-qiang Wang,et al.  Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators. , 2020, Clinics and research in hepatology and gastroenterology.

[5]  Liangdan Sun,et al.  Genome‐wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis , 2019, Hepatology.

[6]  J. Anaya,et al.  Molecular mimicry and autoimmunity. , 2018, Journal of autoimmunity.

[7]  J. Boyer,et al.  Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[8]  J. Fang,et al.  The risk predictive values of UK‐PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti‐gp210 , 2017, Alimentary pharmacology & therapeutics.

[9]  Jing-Yuan Fang,et al.  Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy , 2017, Gut.

[10]  T. Saibara,et al.  Autoantibody status and histological variables influence biochemical response to treatment and long‐term outcomes in Japanese patients with primary biliary cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  A. Granito,et al.  Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[12]  Minoru Nakamura.  Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis , 2014, Seminars in Liver Disease.

[13]  I. Mackay,et al.  Epitope‐specific anti‐nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine‐dependent , 2012, Clinical and experimental immunology.

[14]  C. Selmi,et al.  Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature , 2012, Clinical Reviews in Allergy & Immunology.

[15]  A. Granito,et al.  Antinuclear antibodies as ancillary markers in primary biliary cirrhosis , 2012, Expert review of molecular diagnostics.

[16]  H. Nagamune,et al.  The role of CD18 in the production and release of neutrophils from the bone marrow , 2010, Laboratory Investigation.

[17]  A. Granito,et al.  Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis , 2009, Autoimmunity.

[18]  D. Vergani,et al.  Anti‐gp210 antibody mirrors disease severity in primary biliary cirrhosis , 2007, Hepatology.

[19]  Masahiro Ito,et al.  Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis , 2007, Hepatology.

[20]  R. Chapman,et al.  Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim‐like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis , 2006, Alimentary pharmacology & therapeutics.

[21]  Masahiro Ito,et al.  Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. , 2006, Journal of autoimmunity.

[22]  K. Migita,et al.  Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. , 2005, Journal of hepatology.

[23]  Wolfram Antonin,et al.  The integral membrane nucleoporin pom121 functionally links nuclear pore complex assembly and nuclear envelope formation. , 2005, Molecular cell.

[24]  S. Matsushita,et al.  Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. , 2003, Gastroenterology.

[25]  K. Miyachi,et al.  Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. , 2003, Journal of autoimmunity.

[26]  G. Bianchi,et al.  Characterization and Clinical Impact of Antinuclear Antibodies in Primary Biliary Cirrhosis , 2003, American Journal of Gastroenterology.

[27]  M. Manns,et al.  The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. , 1998, Journal of hepatology.

[28]  H. Asakura,et al.  Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis , 1998 .

[29]  M. Manns,et al.  Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. , 1997, Journal of autoimmunity.

[30]  J. Courvalin,et al.  Specificity and sensitivity of gp210 autoantibodies detected using an enzyme‐linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis , 1996, Hepatology.

[31]  H. Worman,et al.  Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210 , 1993, The Journal of experimental medicine.

[32]  G. Blobel,et al.  The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. , 1990, The Journal of clinical investigation.

[33]  U. Greber,et al.  A major glycoprotein of the nuclear pore complex is a membrane‐spanning polypeptide with a large lumenal domain and a small cytoplasmic tail. , 1990, The EMBO journal.

[34]  G. Blobel,et al.  Primary structure analysis of an integral membrane glycoprotein of the nuclear pore , 1989, The Journal of cell biology.

[35]  M. Plana,et al.  Autoantibodies against nuclear envelope‐associated proteins in primary biliary cirrhosis , 1988, Hepatology.

[36]  M. Kaplan,et al.  Primary Biliary Cirrhosis , 1987, The New England journal of medicine.

[37]  A. Floreani,et al.  Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis , 1985, Journal of Clinical Immunology.

[38]  N. Ling,et al.  Vesicular stomatitis virus glycoprotein is anchored in the viral membrane by a hydrophobic domain near the COOH terminus. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Simons,et al.  Location of the spike glycoproteins in the Semliki Forest virus membrane. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. A. Jabbar,et al.  Structural domains and organizational conformation involved in the sorting and transport of influenza virus transmembrane proteins. , 1989, Annual review of microbiology.

[41]  Chinese Medical Association , 2022, Nature.

[42]  E. Hitchman,et al.  Brief Definitive Report Autoantibodies from Patients with Primary Biliary Cirrhosis Preferentially React with the Amino-terminal Domain of Nuclear Pore Complex Glycoprotein Gp210 , 2022 .